186406-53-1

Upstream product

• 135840-16-3 (2S,4S,5S)-4-hydroxymethyl-2-phenyl-5-(2-propenyl)-1,3-dioxacyclohexane 
• 1125-88-8 benzaldehyde dimethyl acetal 

Downstream Products

• 135840-32-3 (S)-1-[2-{(2R,3R,5S,6R)-6-[(E)-(1S,3S,7R)-7-(tert-Butyl-dimethyl-silanyloxymethyl)-1-methoxy-3,5-dimethyl-deca-5,9-dienyl]-2-hydroxy-5-methoxy-3-methyl-tetrahydro-pyran-2-yl}-2-(4-methoxy-benzyloxy)-acetyl]-piperidine-2-carboxylic acid methyl ester 
• 186406-69-9 ((E)-(2R,6S,8R,9R,10S,12R)-2-Allyl-9,13-bis-benzyloxy-8,10-dimethoxy-4,6,12-trimethyl-tridec-3-enyloxy)-tert-butyl-dimethyl-silane 
• 186406-68-8 (E)-(2R,4S,5R,6R,8S,12R)-1,5-Bis-benzyloxy-12-(tert-butyl-dimethyl-silanyloxymethyl)-4-methoxy-2,8,10-trimethyl-pentadeca-10,14-dien-6-ol 
• 186406-67-7 (E)-(2R,4S,5S,8S,12R)-7-Benzenesulfonyl-1,5-bis-benzyloxy-12-(tert-butyl-dimethyl-silanyloxymethyl)-4-methoxy-2,8,10-trimethyl-pentadeca-10,14-dien-6-one 
• 186406-66-6 (E)-(2R,4S,5R,8S,12R)-7-Benzenesulfonyl-1,5-bis-benzyloxy-12-(tert-butyl-dimethyl-silanyloxymethyl)-4-methoxy-2,8,10-trimethyl-pentadeca-10,14-dien-6-ol 
• 135840-28-7 (2R,4S,5S,8S,10E,12R)-1,5-dibenzyloxy-12-(tert-butyldimethylsilyl)oxymethyl-4-methoxy-2,8,10-trimethyl-10,14-pentadecadien-6-one 
• 186406-60-0 (4R,5E,8S,10S,11R,12S,14R)-11,15-dibenzyloxy-4-(tert-butyldimethylsilyl)oxymethyl-10,12-dimethoxy-6,8,14-trimethyl-1,5-pentadecadiene 
• 135840-29-8 (2R,4S,5R,6S,8S,10E,12R)-1,5-dibenzyloxy-12-(tert-butyldimethylsilyl)oxymethyl-4-methoxy-2,8,10-trimethyl-10,14-pentadecadien-6-ol 
• 135840-21-0 (4R,5E,8S)-4-(tert-butyldimethylsilyl)oxymethyl-6,8-dimethyl-9-(phenylsulfonyl)-1,5-nonadiene 
• 186406-54-2 (2S,4S,5S)-4-acetyl-2-phenyl-5-(2-propenyl)-1,3-dioxacyclohexane 
• 135840-17-4 (2S,4S,5S)-4-isopropenyl-2-phenyl-5-(2-propenyl)-1,3-dioxacyclohexane 
• 186406-63-3 1-((2S,4S,5S)-5-Allyl-2-phenyl-[1,3]dioxan-4-yl)-ethanol 

Relevant academic research and scientific papers

Stereocontrolled synthesis of C10-C22 fragment of the immunosuppressant FK 506. An occurrence of complementary stereoselectivity in the C15 ketone reduction

The stereoselective syntheses of the C10-C22 fragment 2a and its C15-epimer 2b of the immunosuppressant FK 506 1 have been carried out through convergent coupling of the sulfone 3, which could be constructed by highly stereocontrolled ester-enolate Claise

E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose

Provided herein are glycomimetic E-selectin antagonist compounds of formula (I)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising at least one macro

E-SELECTIN ANTAGONISTS MODIFIED BY MACROCYCLE FORMATION TO THE GALACTOSE

Provided herein are glycomimetic E-selectin antagonist compounds of formula (I)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising at least one macro

A Synthesis of C1-C22 Fragment of the Immunosuppressant FK 506. Stereoselective Construction of (E)-Trisubstituted Double Bond (C19-C20) via Ester-enolate Claisen Rearrangement

An ene-ester 5 prepared from L-malic acid was subjected to the ester-enolate Claisen rearrangement under Ireland's condition to give stereoselectively C16-C22 fragment 11 containing (E)-trisubstituted double bond which was further advanced to C1-C22 fragm